Clinical Trial: A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping(R) Lingchang(R)) for the Treatment of Chronic Obstructive Pulmonary Disease

U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07633314) titled 'A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping(R) Lingchang(R)) for the Treatment of Chronic Obstructive Pulmonary Disease' on June 03.

Brief Summary: This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic obstructive pulmonary disease, and to observe the symptoms and pharmacokinetic (PK) characteristics of participants.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: ...